Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inhaled Steroid Growth Effect Should Not Discourage First-Line Use - Cmte.

Executive Summary

Suppression of growth velocity in pediatric asthma patients should not discourage the first-line use of inhaled corticosteroids, FDA's Pulmonary & Allergy and Endocrine & Metabolism Drugs Advisory Committees determined July 31 at a joint meeting.

You may also be interested in...

Muro/Adams Tri-Nasal Launch Planned For Fall Allergy Season With 250 Reps

Muro Pharmaceuticals is increasing production to launch its Tri-Nasal intranasal steroid medication by the start of the fall allergy season.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts